Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial
| Title: | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial |
|---|---|
| Authors: | Popat, Rakesh, Brown, Sarah R, Flanagan, Louise, Hall, Andrew, Gregory, Walter, Kishore, Bhuvan, Streetly, Matthew, Oakervee, Heather, Yong, Kwee, Cook, Gordon, Low, Eric, Cavenagh, Jamie |
| Source: | In The Lancet Haematology December 2016 3(12):e572-e580 |
| Database: | ScienceDirect |
| ISSN: | 23523026 |
|---|---|
| DOI: | 10.1016/S2352-3026(16)30165-X |
| Published in: | The Lancet Haematology |
| Language: | English |